Effect of Clopidogrel vs. Placebo, on a Background of Standard Care including Aspirin, in Maintining the Patency of Lower Limb Arteries After Angioplasty

Study of:
clopidogrel (Plavix); sponsored by Sanofi-Synthelabo, Inc., Briston-Myers Squibb Company

This study is to evaluate whether clopidogrel (Plavix) (on a background of standard care including ASA) will lead to an increase, compared with placebo (on a background of standard care including ASA), in the combined rate of primary patency or survival in subjects following percutaneous transluminal angioplasty (PTA) for the treatment of peripheral arterial disease (PAD).

Patients who meet inclusion criteria will be randomized within 3 hours after their procedure to receive the loading dose of clopidogrel (Plavix) vs. a placebo with low dose (81-162 mg) ASA. Patients will continue on the study drug vs. placebo for the remainder of the study.

• Daniel Lips, MD, FACC
• Yale Wang, MD, FACC, FSCAI

• Talia Pierce, RN
• Denise Windenburg, CCRC

For more information about this or other research studies at the Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, please contact:

Denise Windenburg
612-863-3816
or
Talia Pierce
612-863-8200